NovAccel Established U.S. Nuclear Subsidiary
The Japanese firm expanded its North American operations to boost the supply of medical radioisotopes.
Updated on Sept. 21, 2026 in Nuclear
Live Poll
Do you support companies prioritizing international expansion to improve the global supply of medical treatments?
Japanese technology company NovAccel has launched a new U.S. subsidiary, NovAccel Isotopes Inc., to facilitate growth in North America. This expansion aims to bolster the global supply of actinium-225, a critical component in medical research and treatments.
Why it matters
The move is designed to support the development of medical manufacturing and supply chains across the United States. By establishing a local entity, the company intends to increase its footprint in the North American healthcare and isotope market.
NovAccel specializes in a proprietary compact superconducting accelerator used for producing medical radioisotopes. The company maintains its corporate headquarters in Tsuchiura City, Ibaraki Prefecture, Japan.
The players
Arnaud Lesegretain
He serves as the CEO of NovAccel Isotopes Inc. and also holds the position of Chief Commercial and Business Officer at the parent company NovAccel, Inc.
Takashi Mizukami
He is the Director and Chief Strategy Officer of NovAccel, Inc. and has a professional background spanning two decades in the resource industry.
The details
NovAccel Isotopes Inc. was incorporated in Delaware in July 2026 to manage customer engagement and business development. The firm’s leadership team includes CEO Arnaud Lesegretain, based in New Jersey, and Director Takashi Mizukami, who brings 20 years of experience from the resource industry.
Timeline
July 2026: NovAccel Isotopes Inc. was incorporated in Delaware.
September 21, 2026: The establishment of the new U.S. subsidiary was officially announced.
2027: NovAccel plans to begin operations at its new Hiroshima facility.
Deeper Dive
The expansion follows the industry pattern of scaling up infrastructure to meet the rising global demand for actinium-225 manufacturing. This subsidiary establishment serves as a critical step in building the supply chains necessary for the adoption of next-generation medical isotopes.
The increased availability of actinium-225 could eventually expedite the development of targeted cancer therapies. These advancements may lead to more effective treatment options for patients in the future.
The takeaway
The creation of a U.S.-based entity reflects a broader strategic pivot toward localized manufacturing in the medical isotope sector. This ensures more reliable supply chains for critical health technologies as production capacities continue to evolve.
What happens next
NovAccel plans to initiate operations at its new manufacturing facility in Hiroshima in 2027.
Further reading
Learn more about the latest developments in Nuclear technology and industry infrastructure.
More information
For inquiries, visit the NovAccel public relations contact portal.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you support companies prioritizing international expansion to improve the global supply of medical treatments?
